

5<sup>th</sup> Vaccine and ISV Annual Global Congress Oral Programme

## Sunday 2 October 2011

08:30 - 18:00	Conference Registration   <i>Grand Pacific Ballroom Foyer</i>
10:30 – 12:20	Opening Session & Plenary Session 1   <i>Grand Pacific Ballroom A-D</i> Title: Setting the Scene Session Chair: Ray Spier
10:30 – 10:45	Opening Remarks: Floris de Hon <i>Vaccine</i> and Shan Lu <i>ISV</i>
10:45 – 11:15	[O1.1] A dual mandate: Balancing emerging and persistent infectious diseases Carole A. Heilman, <i>National Institutes of Health, USA</i>
11:15 – 11:45	[O1.2] Vaccines are Miracles: a view from Seattle Jose Esparza, <i>Gates Foundation, USA</i>
11:45 – 12:15	[O1.3] Future of vaccination – Basic sciences Ruth Arnon, <i>The Weizmann Institute of Science, Israel</i>
12:30 – 14.00	Lunch
14:00 – 15:30	Plenary Session 2   <i>Grand Pacific Ballroom A-D</i> Title: New advances in B cells and mAb studies Session Chair: Emilio Emini
14:00 – 14:25	[O2.1] Dissecting the human T and B cell response to pathogens Antonio Lanzavecchia, <i>Institute for Research in Biomedicine, Switzerland</i>
14:25 – 14:50	[O2.2] Human neutralizing monoclonal antibodies and what they teach us about vaccine design James E. Crowe, <i>Vanderbilt University, USA</i>
14:50 – 15:00	[O2.3] Optimizing exposure of the neutralization-competent structure of the HIV-1 gp41 membrane proximal external region J.K. Scott <sup>*1</sup> , N. Gulzar <sup>1</sup> , M. Montero <sup>1</sup> , K-A. Klaric <sup>1</sup> , J. Donald <sup>2</sup> , S. Wang <sup>3</sup> , <sup>1</sup> <i>Simon Fraser University, Canada</i> , <sup>2</sup> <i>University of Pennsylvania, USA</i> , <sup>3</sup> <i>University of Massachusetts Medical School, USA</i> , <sup>4</sup> <i>University of Toronto, Canada</i> , <sup>5</sup> <i>The Scripps Research Institute, USA</i> , <sup>6</sup> <i>University of Pittsburgh, USA</i> , <sup>7</sup> <i>National Cancer Institute, USA</i>
15:00 – 15:10	[O2.4] Neutralizing antibody responses in key HIV-1 vaccine trials C. Karnasuta <sup>*1</sup> , D-C. Montefiori <sup>2</sup> , N. Karasavva <sup>1</sup> , V-R. Polonis <sup>3</sup> , <sup>1</sup> <i>U.S. Army Medical Component -Armed Forces Research Institute of Medical Sciences, Thailand</i> , <sup>2</sup> <i>Duke University Medical Center, USA</i> , <sup>3</sup> <i>Walter Reed Army Institute of Research, USA</i>
15:10 – 15:20	[O2.5] A human monocyte-derived macrophage model system to study the neutralization of HIV-1 by anti-lipid and anti-mper monoclonal antibodies M. Rao <sup>*1</sup> , O. Jobe <sup>2,1</sup> , K. Peachman <sup>2,1</sup> , G. Matyas <sup>1</sup> , L. Asher <sup>2,1</sup> , C. Alving <sup>1</sup> , <sup>1</sup> <i>Walter Reed Army Institute of Research, US Military HIV Research Program, USA</i> , <sup>2</sup> <i>Henry M. Jackson Foundation for the Advancement of Military Medicine, USA</i>
15:20 – 15:30	[O2.6] Robust DNA vaccine +/- protein boost delivered by EP expands B and T cell responses in humans and animals and can induce neutralizing immune responses in vivo K. Muthumani <sup>1</sup> , K-E. Broderik <sup>2</sup> , J. Yan <sup>2</sup> , A. Parikh <sup>1</sup> , X. Shen <sup>2</sup> , D-B. Weiner <sup>*1</sup> , <sup>1</sup> <i>University of Pennsylvania, USA</i> , <sup>2</sup> <i>Inovio, USA</i>
15:30 – 16:00	Refreshment Break
16:00 – 18:00	Plenary Session 3   <i>Grand Pacific Ballroom A-D</i> Title: Vaccines for Global Health Session Chair: Rick Bright
16:00 – 16:25	[O3.1] Realizing the full impact of rotavirus vaccines Duncan Steele, <i>PATH, USA</i>
16:25 – 16:50	[O3.2] DNA priming immunization: A powerful approach to elicit high quality protective antibodies for vaccine development Shan Lu, <i>University of Massachusetts Medical School, USA</i>
16:50 – 17:00	[O3.3] Live recombinant attenuated <i>Salmonella</i> vaccines against <i>Mycobacterium tuberculosis</i> J.E. Clark-Curtiss <sup>*</sup> , M.D. Juarez-Rodriguez, J. Yang, R. Kader, P. Alamuri, R. Curtiss III, <i>Arizona State University, USA</i>

17:00 – 17:10	<b>[O3.4] A novel therapeutic and prophylactic vaccines against tuberculosis using the cynomolgus monkey model and mouse model</b> M. Okada* <sup>1</sup> , T. Nakajima <sup>2</sup> , Y. Kaneda <sup>3</sup> , P. Saunderson <sup>4</sup> , E. Tan <sup>4</sup> , <sup>1</sup> National Hospital Organization Kinki-chuo Chest Medical Center, Japan, <sup>2</sup> Genomidea Co, Japan, <sup>3</sup> Osaka University, Japan, <sup>4</sup> Leonard Wood Memorial Institute, The Philippines, <sup>5</sup> Texas A&M University, United States Minor Outlying Islands
17:10 – 17:20	<b>[O3.5] Immunogenicity of investigational Hepatitis B vaccine (1018 ISS-HBsAg) compared to licensed Hepatitis B vaccine (Engerix-B) in adults ages 40 -70 years</b> W. Heyward*, R. Janssen, S. Bennett, F. Xie, E. Fung, J.T. Martin, <i>Dynavax Technologies Corporation, USA</i>
17:20 – 17:30	<b>[O3.6] Post-exposure efficacy of an adenoviral-based ebola virus vaccine in the mouse, guinea pig and non human primate animal models</b> J. Richardson* <sup>1</sup> , J. Ennis <sup>3</sup> , J. Turner <sup>3</sup> , G. Kobinger <sup>1,2</sup> , <sup>1</sup> Canadian Science Centre for Human and Animal Health, Canada, <sup>2</sup> University of Manitoba, Canada, <sup>3</sup> Defyus Inc, Canada
17:30 – 17:40	<b>[O3.7] Patent landscape: The case of Dengue vaccine patents in Brazil</b> P. Rohem-Santos* <sup>1,2</sup> , C.I. Chamas <sup>1,3</sup> , <sup>1</sup> UFRJ - Federal University of Rio de Janeiro, Brazil, <sup>2</sup> INPI - National Institute of Industrial Property, Brazil, <sup>3</sup> Fiocruz - Oswaldo Cruz Foundation, Brazil
17:40 – 17:50	<b>[O3.8] TBD</b>
18:00 – 20:00	<b>Poster/Exhibition Session 1 and Welcome Reception   Grand Pacific Ballroom E-G and the Grand Pacific Ballroom Foyer</b>

## Monday 3 October 2011

08:30 - 18:00	<b>Conference Registration   Grand Pacific Ballroom Foyer</b>		
08:30 – 10:30	<b>Plenary Session 4   Grand Pacific Ballroom A-D</b> Title: Vaccine Adjuvants Session Chair: Annie DeGroot		
08:30 – 08:55	<b>[O4.1] Highly effective generic adjuvant systems</b> Carl R. Alving, <i>Walter Reed Army Institute of Research, USA</i>		
08:55 – 09:20	<b>[O4.2] Rational design and evaluation of new adjuvants</b> Steven G. Reed, <i>Immune Design Corp., USA</i>		
09:20 – 09:45	<b>[O4.3] CAF01, a novel versatile liposome adjuvant in clinical trials that promote both strong humoral and CMI responses</b> Peter L. Andersen, <i>Statens Serum Institut, Denmark</i>		
09:45 – 09:55	<b>[O4.4] A novel adjuvant platform based on genetically detoxified lipopolysaccharides from <i>Neisseria meningitidis</i></b> P. Van der Ley*, F. Fransen, E. Pupo Escalona, H.J. Hamstra, G. Van den Dobbelsteen, L. Van Alphen, <i>RIVM, The Netherlands</i>		
09:55 – 10:05	<b>[O4.5] Small molecule agonists of the RIG-I pathway that modulate innate immunity as potential novel adjuvants</b> M.L. Wang* <sup>1</sup> , K. Bedard <sup>1</sup> , Y.M. Loo <sup>2</sup> , M.G. Katze <sup>2</sup> , M. Gale Jr. <sup>2</sup> , S.P. Iadonato <sup>1</sup> , <sup>1</sup> Kineta, Inc., USA, <sup>2</sup> University of Washington, USA		
10:05 – 10:15	<b>[O4.6] Adjuvant effects of C3d are mediated through the activation of C3d-specific autoreactive T-cells</b> L. Levitz* <sup>1</sup> , T. Messitt <sup>1</sup> , E. McClaine <sup>1</sup> , R. Tassone <sup>1</sup> , M. Ardito <sup>1</sup> , J.E. Buhlmann <sup>1</sup> , L. Moise <sup>1,2</sup> , P.M. Knopf <sup>3</sup> , W. Martin <sup>1</sup> , A.S. De Groot <sup>1,2</sup> , <sup>1</sup> EpiVax, Inc., USA, <sup>2</sup> University of Rhode Island, USA, <sup>3</sup> Brown University, USA		
10:15 – 10:25	<b>[O4.7] Effects of different adjuvant formulations on cellular migration, maturation and antigen trafficking from the site of vaccination</b> M.J. De Veer* <sup>1</sup> , M. Elhay <sup>2</sup> , E.N. Meeusen <sup>1</sup> , <sup>1</sup> Monash University, Australia, <sup>2</sup> Pfizer Animal Health, Australia		
10:30 – 11:00	<b>Refreshment Break  </b>		
11:00 – 12:30	<b>Breakout Session 1   Grand Pacific Ballroom A-C</b> Title: JSV joint Session Session Chair: Hiroshi Kiyono		<b>Breakout Session 2   Grand Pacific Ballroom D</b> Title: Veterinary Vaccines and animal models Session Chair: Clarisa Palatnik de Sousa
11:00 – 11:25	<b>[B1.1] Impact of prophylactic vaccination with Sendai viral vectors on post-challenge CTL responses in a macaque AIDS model</b> Tetsuro Matano, <i>National Institute of Infectious Diseases, Japan</i>	11:00 – 11:25	<b>[B2.1] Vaccination against babesiosis: What is the impact on malaria vaccine development?</b> Theo Schetters, <i>Intervet, The Netherlands</i>

11:25 – 11:50	<b>[B1.2] The protective effects of intranasal vaccination on influenza virus infection in mice, monkeys, and humans</b> Akira Aina, <i>National Institute of Infectious Diseases, Japan</i>	11:25 – 11:50	<b>[B2.2] H5N1 avian influenza vaccines</b> Hualan Chen, <i>Chinese Academy of Agricultural Sciences, China</i>
11:50 – 12:00	<b>[B1.3] Development of an Influenza HA-flagellin fusion vaccine with down regulated cytokine activity improving safety and immune response</b> D.N. Taylor <sup>*1</sup> , S. Umlauf <sup>1</sup> , L. Tussey <sup>1</sup> , J.J. Treanor <sup>2</sup> , U. Kavita <sup>1</sup> , L. Song <sup>1</sup> , K. Ozer <sup>3</sup> , <sup>1</sup> VaxInnate Corp, USA, <sup>2</sup> Univ of Rochester, USA, <sup>3</sup> Cytel, USA	11:50 – 12:00	<b>[B2.3] New live vaccine against Foot-and-Mouth Disease based on recombinant canine adenovirus type 2</b> X.C. Zhou, M. Carocci, J. Richardson, L. Bakkali-Kassimi, S. Zientara, B. Klonjowski*, <i>UMR 1161 Virologie Anses Inra Enva, France</i>
12:00 – 12:10	<b>[B1.4] Induction of HIV-1 vaccine-specific cell mediated immunity in immune suppressed recipients: <i>Listeria</i> as a vaccine vector</b> L.M. McEwen <sup>*1</sup> , C.T. Bui <sup>1</sup> , Y. Paterson <sup>2</sup> , D.A. Harn <sup>1</sup> , <sup>1</sup> University of Georgia, USA, <sup>2</sup> University of Pennsylvania, USA	12:00 – 12:10	<b>[B2.4] Replication-defective flavivirus vaccine vectors expressing rabies virus G protein, RepliVax®-RabG</b> M. Giel-Moloney*, A.A. Rumyantsev, Q.S. Gao, J. Catalan, Y. Lui, K.V. Pugachev, <i>Sanofi Pasteur, USA</i>
12:10 – 12:20	<b>[B1.5] Computationally Optimized Broadly Reactive Antigen (COBRA): A novel strategy for developing a broadly reactive vaccine against emerging H5N1 and H1N1 influenza</b> B.M. Giles, C.J. Crevar, S.J. Bissel, C.A. Wiley, T.M. Ross*, <i>University of Pittsburgh, USA</i>	12:10 – 12:20	<b>[B2.5] Protective efficacy of a recombinant HVT-H5 vaccine against lethal H5N1 and H5N2 avian influenza challenge</b> D.R. Kapczynski <sup>*1</sup> , M. Esaki <sup>2</sup> , K.M. Dorsey <sup>2</sup> , M.W. Jackwood <sup>3</sup> , Y. Gardin <sup>2</sup> , <sup>1</sup> USDA-ARS, USA, <sup>2</sup> CEVA-Biomune, USA, <sup>3</sup> University of Georgia, USA
12:20 – 12:30	<b>[B1.6] A replication-deficient influenza vaccine based on deletion of M2</b> Y. Hatta <sup>*1</sup> , J. Mooney <sup>1</sup> , S. Watanabe <sup>2</sup> , G. Neumann <sup>2</sup> , Y. Kawaoka <sup>2</sup> , P. Bilsel <sup>1</sup> , <sup>1</sup> FluGen, Inc., USA, <sup>2</sup> University of Wisconsin-Madison, USA	12:20 – 12:30	<b>[B2.6] Immunogenicity of mucosal delivered <i>Lactobacillus casei</i> expressing swine rotavirus protein (VP7)</b> J.S. Lee <sup>*1</sup> , E.H. Kim <sup>1</sup> , J.H. Kim <sup>1</sup> , M.E. Park <sup>1</sup> , M.H. Sung <sup>2</sup> , C.J. Kim <sup>1</sup> , <sup>1</sup> Chungnam National University, Republic of Korea, <sup>2</sup> Kookmin University, Republic of Korea
12:30 – 14:00	<b>Lunch  </b>		
13:30 – 15:30	<b>Poster and Exhibition Session 2   Grand Pacific Ballroom E-G and the Grand Pacific Ballroom Foyer</b>		
14:00 – 15:00	<b>ISV Annual General Meeting (open)   Grand Pacific Ballroom D</b> Chair: Ray Spier		
15:30 – 17:20	<b>Plenary Session 5   Grand Pacific Ballroom A-D</b> <b>Title: Vaccine pipelines – against bacterial targets</b> <b>Session Chair: Alan Barrett</b>		
15:30 – 15:55	<b>[O5.1] Discovering antigens for novel and improved bacterial vaccines</b> John Shiver, <i>Merck Research Laboratories, USA</i>		
15:55 – 16:20	<b>[O5.2] Development of a novel multi-antigen vaccine to prevent <i>Staphylococcus aureus</i> infection and disease</b> Kathrin U. Jansen, <i>Pfizer Vaccine Research, USA</i>		
16:20 – 16:30	<b>[O5.3] Maternal vaccination against bacterial GAPDH prevents neonatal disease caused by Group B <i>Streptococcus</i></b> P. Madureira <sup>*1,2</sup> , E.B. Andrade <sup>1,2</sup> , L. Oliveira <sup>1,2</sup> , A. Ribeiro <sup>1,2</sup> , M. Correia-Neves <sup>3</sup> , P. Trieu-Cuot <sup>4</sup> , <sup>1</sup> ICBAS, University of Porto, Portugal, <sup>2</sup> IBMC, University of Porto, Portugal, <sup>3</sup> Minho University, Portugal, <sup>4</sup> Institut Pasteur, France		
16:30 – 16:40	<b>[O5.4] A chimeric vaccine prevents primary and recurrent <i>Clostridium difficile</i> infection</b> H. Wang <sup>1,2</sup> , X. Sun <sup>1</sup> , Y. Zhang <sup>1</sup> , L. Shi <sup>1</sup> , K. Chen <sup>1</sup> , H. Feng <sup>*1</sup> , <sup>1</sup> Tufts University, USA, <sup>2</sup> The University of Texas Medical Branch, USA		
16:40 – 16:50	<b>[O5.5] MetaVaccinology: A new bacterial vaccine discovery tool</b> E. Altindis <sup>*1,2</sup> , R. Cozzi <sup>1</sup> , S. Marchi <sup>1</sup> , R. Mishra <sup>1</sup> , F. Falugi <sup>1</sup> , D. Maione <sup>1</sup> , F. Bagnoli <sup>1</sup> , G. Grandi <sup>1</sup> , N. Mikkel <sup>1</sup> , S. Liberatori <sup>1</sup> , <sup>1</sup> Novartis Vaccines and Diagnostics, Italy, <sup>2</sup> Harvard Medical School, USA		

16:50– 17:00	<b>[O5.6] Construction and characterization of cholera toxin A2/B chimeras as potential mucosal Staphylococcal vaccines</b> B.M. Arlian, J.K. Tinker*, <i>Boise State University, USA</i>
17:00 – 17:10	<b>[O5.7] <i>Campylobacter jejuni</i> polysaccharide-conjugate vaccine protects against heterologous infection within a serotype complex</b> M.A. Monteiro* <sup>1</sup> , Y.H. Chen <sup>1</sup> , R.C. Maves <sup>2</sup> , M.J. Gregory <sup>2</sup> , G. Nunez <sup>2</sup> , N. Espinoza <sup>2</sup> , <sup>1</sup> <i>University of Guelph, Canada</i> , <sup>2</sup> <i>United States Naval Medical Center, USA</i>
17:10 – 17:20	<b>[O5.8] Collaborations in vaccine development: Partnering pays – A CRO perspective</b> Rangappa Ramachandra, <i>Covance, USA</i>
19:00	Congress Dinner

Tuesday 4 October 2011			
08:30 - 12:30	Conference Registration   <i>Grand Pacific Ballroom Foyer</i>		
08:30 – 10:30	Plenary Session 6   <i>Grand Pacific Ballroom A-D</i> Title: Vaccine pipeline – against viral targets Session Chair: John Shiver		
08:30 – 08:55	<b>[O6.1] Correlates of viral vaccine immunity</b> Stanley Plotkin, <i>Vaxconsult, USA</i>		
08:55 – 09:20	<b>[O6.2] The Sanofi Pasteur Tetravalent Dengue Vaccine: An Update</b> Dany DeGrave, <i>Sanofi Pasteur, USA</i>		
09:20 – 09:45	<b>[O6.3] Synthesizing better influenza vaccine seeds</b> Peter Mason, <i>Novartis Vaccines and Diagnostics, USA</i>		
09:45 – 09:55	<b>[O6.4] Long-term and cross-protective influenza immunity with novel virus-like particle vaccines</b> S.M. Kang* <sup>1</sup> , J.M. Song <sup>1</sup> , F.S. Quan <sup>1</sup> , Y.C. Kim <sup>2</sup> , R.O. Donis <sup>3</sup> , M.R. Prausnitz <sup>2</sup> , R.W. Compans <sup>1</sup> , <sup>1</sup> <i>Emory University School of Medicine, USA</i> , <sup>2</sup> <i>Georgia Institute of Technology, USA</i> , <sup>3</sup> <i>Centers for Disease Control and Prevention, USA</i>		
09:55 – 10:05	<b>[O6.5] Long term and memory immune responses to virus-like particle vaccine candidates for respiratory syncytial virus</b> T. Morrison*, M. Schmidt, L. McGinnes, <i>University of Massachusetts Medical School, USA</i>		
10:05 – 10:15	<b>[O6.6] A formalin-inactivated vaccine against herpes simplex viruses (HSV) types 1 and 2 is an active immunological preparation for prevention of viremia and recurrences under chronic forms of herpetic disease</b> I.F. Barinsky*, A.A. Lazarenko, L.M. Alimbarova, <i>D. Ivanovski Institute of Virology, Russia</i>		
10:15 – 10:25	<b>[O6.7] Phase 1 clinical development of universal influenza vaccine (N8295)</b> R. Janssen* <sup>1</sup> , J. Ervin <sup>2</sup> , W. Heyward <sup>1</sup> , S. Tuck <sup>1</sup> , T. Martin <sup>1</sup> , <sup>1</sup> <i>Dynavax Technologies Corporation, USA</i> , <sup>2</sup> <i>The Center for Pharmaceutical Research, USA</i>		
10:30 – 11:00	Refreshment Break		
11:00 – 12:30	<b>Breakout Session 3   <i>Grand Pacific Ballroom A-C</i></b> Title: Progress in Cancer and other novel vaccines Session Chair: Bruce Weniger		<b>Breakout Session 4   <i>Grand Pacific Ballroom D</i></b> Title: Vaccine Safety and human genomics Session Chair: Robert Chen and Ray Spier
11:00 – 11:30	<b>[B3.1] Sipuleucel-T: An autologous cellular immunotherapy for patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer</b> Robert Sims, <i>Dendreon Corporation, USA</i>	11:00 – 11:25	<b>[B4.1] Vaccine safety when dealt with as a Phase IV matter</b> Ray Spier, <i>UK</i>
11:30 – 11:40	<b>[B3.2] Multi-modal active immunotherapy</b> J. Rothman, <i>Advaxis Inc, USA</i>	11:25 – 11:50	<b>[B4.2] Optimal safety assessment system for future vaccines against poverty-related diseases (e.g., HIV, malaria, TB) in developing countries</b> Robert Chen, <i>Centers for Disease Control and Prevention, USA</i>

11:40 – 11:50	<b>[B3.3] Oral replicating Adenovirus serotype 4 vector vaccine for avian influenza induces cellular immune response to influenza H5N1 hemagglutinin and primes for robust HAI response in healthy adults</b> M. Gurwith* <sup>1</sup> , J. Alexander <sup>1</sup> , G. Ishioka <sup>1</sup> , M. Lock <sup>1</sup> , E. Taylor <sup>1</sup> , R. Greenberg <sup>2</sup> , <sup>1</sup> <i>PaxVax, Inc., USA</i> , <sup>2</sup> <i>University of Kentucky, USA</i>	11:50 – 12:00	<b>[B4.3] Statistical considerations in vaccinomics studies</b> Ann Oberg, <i>Rochester, MN, USA</i>
11:50 – 12:00	<b>[B3.4] Amyloid beta-42-mimotope displaying M13 bacteriophage for vaccine vehicle of Alzheimer's disease</b> K. Sugimura, S. Hashiguchi*, T. Osako, S. Kawabata, R. Abe, S. Nakagawa, <i>Kagoshima University, Japan</i>	12:00 – 12:10	<b>[B4.4] Adapting group sequential methods to observational post-licensure safety surveillance: Results of a combination DTap-IPV-Hib vaccine safety study</b> J.C. Nelson <sup>1,2</sup> , O. Yu* <sup>1</sup> , C. Dominguez <sup>1,2</sup> , A.J. Cook <sup>1,2</sup> , D. Peterson <sup>1</sup> , S.K. Greene <sup>3,4</sup> , <sup>1</sup> <i>Group Health Research Institute, USA</i> , <sup>2</sup> <i>University of Washington, USA</i> , <sup>3</sup> <i>Harvard Medical School, USA</i> , <sup>4</sup> <i>Harvard Pilgrim Health Care Institute, USA</i>
12:00 – 12:10	<b>[B3.5] Carbohydrate-based vaccine confers full protection against experimental <i>Trypanosoma cruzi</i> infection</b> A.F. Marques* <sup>1</sup> , L.L. Nohara <sup>1</sup> , L. Ganiko <sup>1</sup> , K.M. Vasquez <sup>1</sup> , L.R. Travassos <sup>1,2</sup> , I.C. Almeida <sup>1</sup> , <sup>1</sup> <i>University of Texas at El Paso, USA</i> , <sup>2</sup> <i>Universidade Federal de Sao Paulo, Brazil</i> , <sup>3</sup> <i>Pacific Northwest Laboratory, USA</i>	12:10 – 12:20	<b>[B4.5] Active surveillance for adverse events following diphtheria-tetanus-acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccination: Interim results from the Vaccine Safety Datalink</b> M.F. Daley* <sup>5</sup> , W.K. Yih <sup>1</sup> , J.M. Glanz <sup>5</sup> , D.L. McClure <sup>5</sup> , S.J. Hambidge <sup>5</sup> , R. Yin <sup>1</sup> , L. Li <sup>1</sup> , J.C. Nelson <sup>1</sup> , J.D. Nordin <sup>1</sup> , N.P. Klein <sup>1</sup> , S.M. Marcy <sup>1</sup> , E. Weintraub <sup>1</sup> , <sup>1</sup> <i>Harvard Pilgrim Health Care, USA</i> , <sup>2</sup> <i>Group Health Cooperative, USA</i> , <sup>3</sup> <i>HealthPartners Research Foundation, USA</i> , <sup>4</sup> <i>Kaiser Permanente Northern California, USA</i> , <sup>5</sup> <i>Kaiser Permanente Colorado, USA</i> , <sup>6</sup> <i>Centers for Disease Control and Prevention, USA</i> , <sup>7</sup> <i>Kaiser Permanente Southern California, USA</i>
12:10 – 12:20	<b>[B3.6] Plant-made influenza virus-like particles: An effective way of producing next generation vaccines</b> N. Landry* <sup>1</sup> , B.J. Ward <sup>2</sup> , L.P. Vézina <sup>1</sup> , S. Trépanier <sup>1</sup> , M. Dargis <sup>1</sup> , M.A. D'Aoust <sup>1</sup> , <sup>1</sup> <i>Medicago inc., Canada</i> , <sup>2</sup> <i>Research Institute of the McGill University Health Center, Canada</i>	12:20 – 12:30	<b>[B4.6] Safety of 17DD yellow fever vaccine in dose-response study</b> R. Martins* <sup>1</sup> , M.L. Maia <sup>1</sup> , R.H. Farias <sup>1</sup> , L.A. Camacho <sup>2</sup> , M. Freire <sup>1</sup> , A. Homma <sup>1</sup> , <sup>1</sup> <i>Bio-Manguinhos, Brazil</i> , <sup>2</sup> <i>Fiocruz, Brazil</i>
12:20 – 12:30	<b>[B3.7] Flow-through purification of viruses-a novel approach for vaccine purification</b> G. Iyer* <sup>1</sup> , S. Ramaswamy <sup>2</sup> , K.S. Cheng <sup>1</sup> , N. Sisowath <sup>1</sup> , U. Mehta <sup>1</sup> , A. Leahy <sup>1</sup> , D. Asher <sup>1</sup> , <sup>1</sup> <i>EMD Millipore, USA</i> , <sup>2</sup> <i>Lonza Biologics Tuas Pte. Ltd, Singapore</i>	12:30 – 12:40	<b>[B4.7] A purpose-built phase 1 isolation facility for conducting human challenge studies with pathogenic microorganisms</b> A. Nolan <sup>1</sup> , E. Allen <sup>1</sup> , D. Wilbraham <sup>1</sup> , K. McKee* <sup>2</sup> , <sup>1</sup> <i>Quintiles Drug Research unit at Guy's Hospital, UK</i> , <sup>2</sup> <i>Quintiles, USA</i>
12:30 – 14:00	Lunch		
12:30 – 14:30	Poster and Exhibition Session 3   <i>Grand Pacific Ballroom E-G and the Grand Pacific Ballroom Foyer</i>		
14:30 – 16:30	Plenary Session 7   <i>Grand Pacific Ballroom A-D</i> Title: Future Vaccine Development and Congress Summary Session Chair: Shan Lu		
14:30 – 14:45	Edward Jenner Poster Prize ceremony		
14:45 – 15:05	<b>[O7.1] Vaccinomics and personalized vaccinology</b> Gregory A. Poland, <i>Mayo Clinic, USA</i>		
15:05 – 15:30	<b>[O7.2] Emerging virus infections and novel intervention strategies</b> Albert Osterhaus, <i>Erasmus MC Rotterdam, The Netherlands</i>		

15:30 – 15:55	<b>[O7.3] Vaccine development, regulatory principles and practices</b> <i>Wellington Sun, U.S. Food and Drug Administration, USA</i>
15:55 – 16:20	<b>[O7.4] Global development and distribution of vaccines relies on the “Knowledge Triangle”, the EIT’s concept to unlock Europe’s innovation potential</b> <i>Alexander Von Gabain, Intercell, Austria</i>
16:20 – 16:30	<b>Closing summary – Ray Spier ISV</b>